Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Rohit LoombaMazen NoureddinKris V KowdleyAnita KohliAasim SheikhGuy NeffBal Raj BhandariNadege GunnStephen H CaldwellZachary GoodmanIlan WapinskiMurray ResnickAndrew H BeckDora DingCatherine JiaJen-Chieh ChuangRyan S HussChuhan ChungG Mani SubramanianRobert P MyersKeyur PatelBrian B BorgReem GhalibHeidi KablerJohn PoulosZiad YounesMagdy ElkhashabTarek HassaneinRajalakshmi IyerPeter RuaneMitchell L ShiffmanSimone StrasserVincent Wai-Sun WongRohit L Loombanull nullPublished in: Hepatology (Baltimore, Md.) (2021)
In patients with bridging fibrosis and cirrhosis, 48 weeks of cilofexor/firsocostat was well tolerated, led to improvements in NASH activity, and may have an antifibrotic effect. This combination offers potential for fibrosis regression with longer-term therapy in patients with advanced fibrosis attributable to NASH.